What are the side effects of amiodarone?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Amiodarone Side Effects

Amiodarone causes serious organ toxicity across multiple systems, with pulmonary toxicity being the most dangerous and potentially fatal adverse effect, requiring vigilant monitoring and often necessitating drug discontinuation. 1

Most Serious Side Effects

Pulmonary Toxicity (Most Life-Threatening)

  • Incidence: 1-17% of patients, with more recent data showing 1% annually for acute respiratory distress syndrome 1
  • Presentation: Subacute cough and progressive dyspnea with patchy interstitial infiltrates on chest radiograph and reduced diffusing capacity 1
  • Critical pitfall: Can develop rapidly without antecedent abnormalities on routine screening tests 1
  • Management: Immediate withdrawal of amiodarone, supportive care, and corticosteroids in some cases; usually reversible if caught early 1

Thyroid Dysfunction

  • Hypothyroidism: 2-4 times more common than hyperthyroidism; occurs in 2-10% of patients 1, 2
    • Can continue amiodarone with thyroid hormone supplementation if clinically indicated 1
  • Hyperthyroidism: Results from iodine excess or acute thyroiditis
    • Requires withdrawal of amiodarone (if safe), antithyroid medications, prednisone, or surgical thyroidectomy 1

Hepatotoxicity

  • Incidence: 0.6% annually for clinically significant toxicity; elevated transaminases in 15-30% 1, 3
  • Action threshold: Discontinue if liver enzymes exceed 3 times normal unless patient is at high risk for life-threatening arrhythmia recurrence 1
  • Presentation: Usually asymptomatic elevation of liver transaminases 1

Cardiovascular Side Effects

Cardiac Conduction Abnormalities

  • Bradycardia and heart block: 1-3% with oral therapy; 4.9% with IV administration 1
  • Proarrhythmia: <1% annually; torsades de pointes is rare despite universal QT prolongation 1
  • Hypotension: 16% with IV administration 1
  • Absolute contraindication: Second- or third-degree heart block without pacemaker 1

Ocular Side Effects

Common but Benign

  • Corneal microdeposits: Present in nearly all patients (>90%) on slit-lamp examination 1, 3
    • Seldom affect vision, rarely require discontinuation 1

Rare but Serious

  • Optic neuropathy/neuritis: ≤1-2% incidence 3
    • Can progress to total permanent blindness 1
    • Immediate action required: Any patient reporting changes in visual acuity or peripheral vision needs urgent ophthalmologic evaluation 1

Dermatologic Side Effects

  • Photosensitivity: Very common (25-75%) 3
    • Prevention: All patients must use sunblock and cover exposed skin outdoors 1
  • Blue-gray skin discoloration: 4-9% with extended sun exposure 3
    • Resolves over several months after discontinuation 1

Neurologic Side Effects

  • Common symptoms: Ataxia, paresthesias, tremor (20-40% of patients) 2
    • Usually dose-related and improve with dose reduction 1
  • Peripheral neuropathy: 0.3% annually 1

Gastrointestinal Side Effects

  • Symptoms: Nausea, anorexia, constipation
  • Management: Dose-related; usually improve with dose reduction 1

Critical Drug Interactions

Warfarin

  • Effect: Sudden and pronounced increases in PT/INR due to CYP2C9 inhibition 1
  • Peak effect: Approximately 7 weeks after initiation 1
  • Monitoring: PT/INR at least weekly during first 6 weeks 1

Digoxin

  • Effect: Levels predictably double due to inhibition of renal tubular secretion 1
  • Action required: Reduce digoxin dose by 50% when starting amiodarone and monitor levels closely 1

Other Important Interactions

  • Inhibits CYP2D6 (beta blockers, narcotics) and CYP3A4 (calcium channel blockers, cyclosporine) 1
  • Avoid grapefruit: Inhibits conversion to active metabolite 1

Essential Monitoring Protocol

Baseline Assessment (Before Starting)

  • Complete history and physical examination
  • Chest radiograph
  • Thyroid studies and liver transaminase levels
  • Pulmonary function tests including DLCO
  • Ophthalmologic examination if preexisting visual impairment
  • Digoxin level, PT/INR if applicable 1

During Loading Phase

  • Close heart rate surveillance, especially first week 1

Every 6 Months (Chronic Therapy)

  • Thyroid studies and liver transaminase levels
  • History and physical examination for adverse effects
  • Chest radiograph and PFTs if pulmonary symptoms develop
  • Ophthalmologic examination if visual symptoms occur 1

Common Pitfalls to Avoid

  1. Don't rely on routine screening for pulmonary toxicity—it can develop rapidly; any patient-reported worsening dyspnea or cough demands immediate assessment 1
  2. Don't confuse congestive heart failure with amiodarone pneumonitis—rule out CHF early in evaluation 1
  3. Don't forget baseline PFTs—only 24% of patients receive this critical test despite guidelines 4
  4. Don't overlook visual complaints—optic neuropathy can cause permanent blindness 1
  5. Don't continue therapy with liver enzymes >3x normal unless arrhythmia is immediately life-threatening 1

References

1
Guideline

amiodarone: guidelines for use and monitoring.

American family physician, 2003

Related Questions

What is the established elimination half‑life of amiodarone?
What antibiotic regimen is appropriate for a female patient taking amiodarone?
What are the indications, dosing regimens, monitoring requirements, contraindications, and alternative therapies for amiodarone?
Can amiodarone cause hot flushes and how should they be managed?
What are the indications, dosing regimen, monitoring requirements, and contraindications for amiodarone?
Can hypogonadism symptoms occur despite normal serum testosterone levels?
What is another name for the anti-platelet antibody test?
What are the contraindications to systemic corticosteroid therapy?
What could be causing nightly anal burning with intermittent diarrhea and how should it be evaluated and managed?
What does a Glial Fibrillary Acidic Protein (GFAP) level of 117 ng/mL, which exceeds the upper limit of 70 ng/mL, indicate?
How should I evaluate and manage a woman presenting with right‑sided rib‑area pain and concurrent anal burning with diarrhea?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.